Last reviewed · How we verify

Part A: Dose Escalation of Cantrixil

Kazia Therapeutics Limited · Phase 1 active Small molecule

Part A: Dose Escalation of Cantrixil is a Small molecule drug developed by Kazia Therapeutics Limited. It is currently in Phase 1 development. Also known as: TRX-E-002-1 in 20% SBECD.

At a glance

Generic namePart A: Dose Escalation of Cantrixil
Also known asTRX-E-002-1 in 20% SBECD
SponsorKazia Therapeutics Limited
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Part A: Dose Escalation of Cantrixil

What is Part A: Dose Escalation of Cantrixil?

Part A: Dose Escalation of Cantrixil is a Small molecule drug developed by Kazia Therapeutics Limited.

Who makes Part A: Dose Escalation of Cantrixil?

Part A: Dose Escalation of Cantrixil is developed by Kazia Therapeutics Limited (see full Kazia Therapeutics Limited pipeline at /company/kazia-therapeutics-limited).

Is Part A: Dose Escalation of Cantrixil also known as anything else?

Part A: Dose Escalation of Cantrixil is also known as TRX-E-002-1 in 20% SBECD.

What development phase is Part A: Dose Escalation of Cantrixil in?

Part A: Dose Escalation of Cantrixil is in Phase 1.

Related